Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clomifene→

Clomifene Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
911-45-5
Molecular formula
C26H28ClNO
Molecular weight
406 g/mol
Drug class
Selective oestrogen-receptor modulator (SERM)non-steroidal ovulation stimulant
Mechanism of action
Interacts with oestrogen receptors in the hypothalamus and alters oestrogen feedback, increasing pituitary gonadotrophin output and promoting ovarian follicular maturation and ovulation.
Indications / reported uses
  • Induction of ovulation in appropriately selected anovulatory or oligo-ovulatory women seeking pregnancy; use requires assessment of the cause of infertility and product-specific eligibility

Sources: UK SmPC — Clomifene 50 mg tablets · US DailyMed — Clomid prescribing information · NCI Drug Dictionary

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clomifene Environmental Risk Assessment (ERA) (the Clomifene ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.